Using clinical specimens from the SOLTI eribulin neoadjuvant trial, we provided proof-of-concept that activation of αSMA and RhoA kinase in intratumoral pericytes and increased vessel integrity are a direct result of eribulin neoadjuvant treatment in TBNC and HR+ breast cancer patients. The gene discussed is ACTA1; the disease is breast carcinoma.